ClinicalTrials.gg
CompletedNCT00252005Updated Mar 2, 2010

Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study

A Phase 2 interventional study of Apixaban in Deep-Vein Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 73 sites in 11 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2010-03-02.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
520
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.

Enrollment
13th of 26
520 · median 445
Started
2005
the only one that year
Phase 2
Only one
of the 26
Registered
2nd of 26
by date
Lead sponsor
6 of 26
Bristol-Myers Squibb

Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 13th largest by enrollment, is the only one that started in 2005, is the only one in phase 2, and was the 2nd registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing apixaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to assess efficacy and safety of 3 doses of apixaban 5 mg twice a day, 10 mg twice a day and 20 mg once daily versus conventional treatment with low molecular weight heparin or fondaparinux and vitamin K antagonist in the treatment of subjects with acute symptomatic deep-vein thrombosis.

03

Conditions studied

  • Deep-Vein Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be willing and able to give written .
  2. Confirmed acute symptomatic DVT, i.e., proximal vein or extensive calf-vein thrombosis, involving at least the upper third part of the deep calf veins (trifurcation area) without concomitant symptomatic PE.
  3. Women and men, ages 18 (or legal age of consent) to 90. Women of (WOCBP) must be using an adequate method of to avoid pregnancy throughout the study and for up to 1 week after the study in such a manner that the risk of pregnancy is minimized.

WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not [defined as amenorrhea for 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35mIU/mL]. Even women who are using oral, implanted or, injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential. WOCBP must have negative serum or urine pregnancy test (minimum sensitivity 25IU/L or equivalent units of HCG) within 24 hours prior to the start of study medication.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding.
  2. Women with a positive pregnancy test on enrollment or prior to study drug administration.
  3. More than 24 hours pre-randomization treatment with therapeutic dosages of unfractionated heparin (UFH), low molecular weight heparin (LMWH) or fondaparinux or more than a single starting dose of vitamin K antagonist (VKA) prior to randomization.
  4. Uncontrolled hypertension: systolic blood pressure > 200 mm Hg or diastolic blood pressure > 110 mm Hg.
  5. \< 30 mL/min
  6. Impaired liver function ( > 3 x )
  7. Use of ASA > 165 mg/day
  8. who are unwilling or unable to use an acceptable method of to avoid pregnancy for the entire study period and for up to 1 week after the study.
  9. Azole antifungals (e.g., ketoconazole), protease inhibitors (e.g., ritonavir) and macrolide antibiotics (e.g., erythromycin).

NOTE: topical azole antifungal agents are permitted.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
520 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The composite of symptomatic recurrent venous thromboembolism (i.e., recurrent deep-vein thrombosis or fatal or non-fatal pulmonary embolism and deterioration of the thrombotic burden as assessed by repeat bilateral

  2. compression ultrasound and perfusion lung scan.

07

Study locations

73 sites
  • Local Institution
    Albuquerque, New Mexico, United States
  • Local Institution
    Chapel Hill, North Carolina, United States
  • Local Institution
    San Antonio, Texas, United States
  • Local Institution
    Fredericksburg, Virginia, United States
  • Local Institution
    Seattle, Washington, United States
  • Local Institution
    Garran, Australian Capital Territory, Australia
  • Local Institution
    Caringbah, New South Wales, Australia
  • Local Institution
    Kogarah, New South Wales, Australia
  • Local Institution
    Randwick, New South Wales, Australia
  • Local Institution
    Bedford Park, South Australia, Australia
  • Local Institution
    Box Hill, Victoria, Australia
  • Local Institution
    Clayton, Victoria, Australia
  • Local Institution
    Melbourne, Victoria, Australia
  • Local Institution
    Perth, Western Australia, Australia
  • Local Institution
    Graz, Austria
  • Local Institution
    Wien, Austria
  • Local Institution
    Hradec Kralove, Czech Republic
  • Local Institution
    Karlovy Vary, Czech Republic
  • Local Institution
    Ostrava 1, Czech Republic
  • Local Institution
    Ostrava Poruba, Czech Republic
  • Local Institution
    Plzen, Czech Republic
  • Local Institution
    Praha 1, Czech Republic
  • Local Institution
    Praha 2, Czech Republic
  • Local Institution
    Usti Nad Labem, Czech Republic
  • Local Institution
    Angers, France
  • Local Institution
    Brest Cedex, France
  • Local Institution
    Clermont-Ferrand Cedex 01, France
  • Local Institution
    Creteil, France
  • Local Institution
    Limoges, France
  • Local Institution
    Montpellier, France
  • Local Institution
    Paris, France
  • Local Institution
    Saint Etienne, France
  • Local Institution
    Afula, Israel
  • Local Institution
    Ashkelon, Israel
  • Local Institution
    Haifa, Israel
  • Local Institution
    Holon, Israel
  • Local Institution
    Jerusalem, Israel
  • Local Institution
    Kfar-Saba, Israel
  • Local Institution
    Petach Tikva, Israel
  • Local Institution
    Safed, Israel
  • Local Institution
    Tel Aviv, Israel
  • Local Institution
    Chieti, Italy
  • Local Institution
    Milano, Italy
  • Local Institution
    Padova, Italy
  • Local Institution
    Pavia, Italy
  • Local Institution
    Piacenza, Italy
  • Local Institution
    Reggio Emilia, Italy
  • Local Institution
    Treviso, Italy
  • Local Institution
    Venezia, Italy
  • Local Institution
    Amsterdam, Netherlands
  • Local Institution
    Arnhem, Netherlands
  • Local Institution
    Groningen, Netherlands
  • Local Institution
    Hoofddorp, Netherlands
  • Local Institution
    Maastricht, Netherlands
  • Local Institution
    Zwolle, Netherlands
  • Local Institution
    Bydgoszcz, Poland
  • Local Institution
    Katowice, Poland
  • Local Institution
    Krakow, Poland
  • Local Institution
    Lublin, Poland
  • Local Institution
    Poznan, Poland
  • Local Institution
    Warszawa, Poland
  • Local Institution
    Wroclaw, Poland
  • Local Institution
    Bloemfontein, Free State, South Africa
  • Local Institution
    Centurion, Gauteng, South Africa
  • Local Institution
    Johannesburg, Gauteng, South Africa
  • Local Institution
    Sunninghill, Gauteng, South Africa
  • Local Institution
    Somerset West, Western Cape, South Africa
  • Local Institution
    Boras, Sweden
  • Local Institution
    Goteborg, Sweden
  • Local Institution
    Halmstad, Sweden
  • Local Institution
    Jonkoping, Sweden
  • Local Institution
    Stockholm, Sweden
  • Local Institution
    Vastervik, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2005
First posted
Nov 11, 2005
Start
Nov 2005
Primary completionActual
Feb 2007
CompletionActual
Feb 2007
Results delay requested
Feb 27, 2010
Last update
Mar 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00252005
First posted
Nov 11, 2005
Start date
Nov 2005
Primary completion
Feb 2007
Completion
Feb 2007
Last update
Mar 2, 2010
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion